Moolec Science SA Faces Potential Dispute with INVIM
Ticker: MLECW · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1937737
Sentiment: neutral
Topics: dispute, contractual-issue, legal
TL;DR
Moolec Science SA in dispute with INVIM over alleged breach of contract.
AI Summary
Moolec Science SA announced on October 2, 2025, that it received a notice of alleged breach from INVIM Corporativo S.L. regarding an Assignment and Assumption Agreement dated May 1st. This notice indicates a potential dispute between the two companies.
Why It Matters
This dispute could impact Moolec Science's contractual obligations and financial standing, potentially affecting investor confidence.
Risk Assessment
Risk Level: medium — A dispute with a contractual partner introduces uncertainty and potential financial or operational repercussions.
Key Players & Entities
- Moolec Science SA (company) — Registrant
- INVIM Corporativo S.L. (company) — Party alleging breach
- October 2, 2025 (date) — Date of notice
- May 1st (date) — Date of agreement
FAQ
What is the specific nature of the alleged breach by Moolec Science SA?
The filing states that Moolec Science SA received a notice of alleged breach, but does not specify the exact nature of the breach in the provided text.
What is the Assignment and Assumption Agreement dated May 1st related to?
The filing mentions an Assignment and Assumption Agreement dated May 1st in relation to the dispute with INVIM Corporativo S.L., but does not detail its subject matter.
What are the potential consequences of this dispute for Moolec Science SA?
The filing does not explicitly state the potential consequences, but a dispute typically implies potential legal action, financial penalties, or reputational damage.
Has Moolec Science SA responded to the notice from INVIM Corporativo S.L.?
The provided text indicates that Moolec Science SA received the notice, but does not mention any specific response or action taken by the company.
Is INVIM Corporativo S.L. a significant partner or entity for Moolec Science SA?
The filing identifies INVIM Corporativo S.L. as a party to an Assignment and Assumption Agreement, suggesting a business relationship, but does not quantify its significance.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 16 · Accepted 2025-10-21 17:20:01
Key Financial Figures
- $13 million — ed to pay the Assignment Price equal to $13 million on the Payment Date of September 30, 20
Filing Documents
- ea0262038-6k_moolec.htm (6-K) — 12KB
- 0001213900-25-100901.txt ( ) — 13KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-41586 MOOLEC SCIENCE SA (Exact name of Registrant as Specified in Its Charter) 89 Nexus Way, Camana Bay Grand Cayman KY1-9009 Cayman Islands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (Registration No. 333-283113) and Form S-8 (Registration No. 333-282263). Moolec Announces Potential Dispute With INVIM On October 2, 2025, the Company received a notice of alleged breach from INVIM Corporativo S.L., a private limited company incorporated under the laws of Spain (“INVIM”), with respect to the certain Assignment and Assumption Agreement, dated May 27, 2025 (the “Agreement”), by and among INVIM, Bioceres Group Limited, a private limited company incorporated under the laws of the United Kingdom (the “Assignee”), Bioceres Tech Services LLC, a limited liability company incorporated and existing under the laws of the State of Delaware (the “Guarantor” and together with the Assignee, the “Obligors”), and Moolec Science Ltd., a limited company incorporated under the laws of the United Kingdom (solely for purposes of Section 2 of the Agreement). That Agreement in turn references related instruments, including a Note Purchase Agreement and a Binding Contribution Memorandum of Understanding, both dated October 15, 2023. INVIM’s letter asserts that the Obligors have failed to pay the Assignment Price equal to $13 million on the Payment Date of September 30, 2025. The Company disagrees with INVIM’s assertion that any payment is due or owing because, among other reasons, under the plain terms of the Agreement and related transaction instruments, INVIM failed to ever satisfy certain conditions precedent, including failing to validly transfer relevant securities or execute a required services agreement. On October 20, 2025, the Company delivered a formal response letter to INVIM, rejecting INVIM’s assertions and reserving all rights. The Company intends to vigorously defend its position and enforce its rights under the Agreement, related transaction instruments, and applicable law. While the Company believes INVIM’s assertions lack merit, if INVIM were to ultimately prevail in proving its assertions in any proceedings, such an adverse outcome could have a material adverse effect on the Company’s business, financial condition, results of operations, or liquidity. The Company will provide further updates as appropriate. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Moolec Science SA (registrant) Date: October 21, 2025 By: /s/ Alejandro Antalich Name: Alejandro Antalich Title: Chief Executive Officer 2